What is LabGenius?
LabGenius is at the forefront of protein engineering, leveraging a proprietary discovery platform named EVATM. This advanced system integrates cutting-edge technologies from computer science, robotic automation, and synthetic biology to accelerate the design and development of novel proteins. Headquartered in London, UK, the company's multidisciplinary team comprises experts in protein engineering, synthetic biology, software engineering, data science, and robotic automation, positioning LabGenius as a key player in the biotechnology sector.
How much funding has LabGenius raised?
LabGenius has raised a total of $73.2M across 3 funding rounds:
Angel/Seed
$3.7M
Series A
$25M
Series B
$44.5M
Angel/Seed (2017): $3.7M with participation from Kindred Capital, Acequia Capital, Beast Ventures, System.One., and Berggruen Holdings
Series A (2020): $25M led by Felicis Ventures, Patrick Pichette, The Obvious, Air Street Capital, Atomico, Chris Gibson, Lux Capital, and Inovia Capital
Series B (2024): $44.5M supported by LG, M/ventures, and Octopus Ventures
Key Investors in LabGenius
Felicis Ventures
Felicis Ventures is a Menlo Park-based venture capital firm that invests in early and growth-stage technology companies across sectors such as SaaS, AI, and fintech, often leading seed and Series A rounds.
Atomico
Atomico is a European Venture Capital firm headquartered in London, with offices in Paris, Berlin and Stockholm, founded by Niklas Zennström, co-founder of Skype.
Lux Capital
Lux Capital is a New York-based venture capital firm investing in early-stage and growth-stage companies at the intersection of science and technology, including AI, robotics, and biotechnology.
What's next for LabGenius?
With its recent major strategic investment, LabGenius is poised for accelerated growth and further development of its EVATM platform. The substantial capital infusion, contextualized as enterprise-level funding, suggests the company is moving beyond its early-stage development and is likely focusing on scaling its operations, expanding its research capabilities, and potentially entering new market segments. This strategic financing will enable LabGenius to further solidify its position in the competitive landscape of ML-driven biotechnology.
See full LabGenius company page
